Knockdown of hsa_circ_0000729 Inhibits the Tumorigenesis of Non-Small Cell Lung Cancer Through Mediation of miR-1281/FOXO3 Axis

Xie, Xian-Jin; Ding, Fang; Xiao, Haibo

doi:10.2147/cmar.s318980

Cited by 2 publications

(2 citation statements)

References 34 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, SNHG3 was found to promote the progression of LUAD by targeting miR-890 [42]. It has also been reported that suppression of hsa_circ_0000729 could induce pyroptosis and tumorigenesis in NSCLC cells by targeting miR-1281/FOXO3 [43]. Furthermore, let-7f-1-3p may act as a suppressor gene targeting integrin β1 and enhance doxorubicin's inhibition on lung cancer cell viability in vitro [44].…”

Section: Discussionmentioning

confidence: 91%

m7G-related miRNA signature for prediction of prognosis in lung adenocarcinoma

Jiang

Shi

Xiao

et al. 2022

Preprint

View full text Add to dashboard Cite

Background N7-methylguanosine (m7G), one of the most conserved nucleotide modifications, presents in mRNA caps and internal sites of tRNAs and rRNAs. Previous data have demonstrated that abnormal m7G is associated with tumorigenesis. Notably, the expression of m7G’s regulators remains unknown in human cancers, especially in lung adenocarcinoma (LUAD). This study aimed to construct a prognostic signature based on m7G-related miRNAs in LUAD and to explore the potential association of the regulators with tumor immune microenvironment (TIME). Methods We used LUAD data from The Cancer Genome Atlas (TCGA) to establish a risk model based on the m7G-related miRNAs, and divided patients into high-risk or low-risk subgroups. A nomogram for predicting overall survival (OS) was then constructed based on the independent risk factors. In addition, we performed functional enrichment analysis and defined the immune landscape as well as drug response profile in the high-risk and low-risk subgroups. Results This study incorporated 28 m7G-related miRNAs into the risk model. The data showed a significant difference in the OS between the high-risk and low-risk subgroups. The receiver operating characteristic curve (ROC) predicted that the area under the curve (AUC) of 1-year, 3-year and 5-year OS was 0.781, 0.804 and 0.853, respectively. The C-index of the prognostic nomogram for predicting OS was 0.739. We then analyzed the immune landscape in the high-risk and low-risk subgroups. The data demonstrated significant differences in the estimated score, immune score, stromal score, immune cell infiltration and functions between the high-risk and low-risk subgroups. In addition, drug response analysis showed that low-risk subgroups may be more sensitive to tyrosine kinase inhibitor (TKI) and histone deacetylase (HDAC) inhibitors. Conclusion We successfully developed a novel risk model based on m7G-related miRNAs in this study. The model can predict clinical prognosis and guide therapeutic regimens in patients with LUAD. Our data also provided new insights into molecular mechanisms of m7G in LUAD.

show abstract

Section: Discussionmentioning

confidence: 91%

m7G-related miRNA signature for prediction of prognosis in lung adenocarcinoma

Jiang

Shi

Xiao

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Notably, SNHG3 was found to promote the progression of LUAD by targeting miR-890 [ 50 ]. It has also been reported that suppression of hsa_circ_0000729 could induce pyroptosis and tumorigenesis in NSCLC cells by targeting miR-1281/FOXO3 [ 51 ]. Furthermore, let-7f-1-3p may act as a suppressor gene targeting integrin β1 and enhance doxorubicin’s inhibition on lung cancer cell viability in vitro [ 52 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of m7G-Related miRNA Signatures Associated with Prognosis, Oxidative Stress, and Immune Landscape in Lung Adenocarcinoma

et al. 2023

View full text Add to dashboard Cite

The role of N7-methylguanosine(m7G)-related miRNAs in lung adenocarcinoma (LUAD) remains unclear. We used LUAD data from The Cancer Genome Atlas (TCGA) to establish a risk model based on the m7G-related miRNAs, and divided patients into high-risk or low-risk subgroups. A nomogram for predicting overall survival (OS) was then constructed based on the independent risk factors. In addition, we performed a functional enrichment analysis and defined the oxidative stress-related genes, immune landscape as well as a drug response profile in the high-risk and low-risk subgroups. This study incorporated 28 m7G-related miRNAs into the risk model. The data showed a significant difference in the OS between the high-risk and low-risk subgroups. The receiver operating characteristic curve (ROC) predicted that the area under the curve (AUC) of one-year, three-year and five-year OS was 0.781, 0.804 and 0.853, respectively. The C-index of the prognostic nomogram for predicting OS was 0.739. We then analyzed the oxidative stress-related genes and immune landscape in the high-risk and low-risk subgroups. The data demonstrated significant differences in the expression of albumin (ALB), estimated score, immune score, stromal score, immune cell infiltration and functions between the high-risk and low-risk subgroups. In addition, the drug response analysis showed that low-risk subgroups may be more sensitive to tyrosine kinase inhibitor (TKI) and histone deacetylase (HDAC) inhibitors. We successfully developed a novel risk model based on m7G-related miRNAs in this study. The model can predict clinical prognosis and guide therapeutic regimens in patients with LUAD. Our data also provided new insights into the molecular mechanisms of m7G in LUAD.

show abstract

Knockdown of hsa_circ_0000729 Inhibits the Tumorigenesis of Non-Small Cell Lung Cancer Through Mediation of miR-1281/FOXO3 Axis

Cited by 2 publications

References 34 publications

m7G-related miRNA signature for prediction of prognosis in lung adenocarcinoma

m7G-related miRNA signature for prediction of prognosis in lung adenocarcinoma

Identification of m7G-Related miRNA Signatures Associated with Prognosis, Oxidative Stress, and Immune Landscape in Lung Adenocarcinoma

Contact Info

Product

Resources

About